M. Lalanne

发表

CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations

G. Cullot, J. Boutin, J. Toutain, 2019, Nature Communications.

A bicistronic SIN‐lentiviral vector containing G156A MGMT allows selection and metabolic correction of hematopoietic protoporphyric cell lines

I. Lamrissi‐Garcia, M. Lalanne, C. Ged, 2003, The journal of gene medicine.

Lentivirus-mediated gene transfer of uroporphyrinogen III synthase fully corrects the porphyric phenotype in human cells

I. Lamrissi‐Garcia, M. Lalanne, C. Ged, 2003, Journal of Molecular Medicine.

Highly Efficient Lentiviral Gene Transfer in CD34+ and CD34+/38−/lin− Cells from Mobilized Peripheral Blood after Cytokine Prestimulation

I. Lamrissi‐Garcia, M. Lalanne, C. Ged, 2003, Stem cells.

Modeling of congenital erythropoietic porphyria by RNA interference: a new tool for preclinical gene therapy evaluation

I. Lamrissi‐Garcia, M. Lalanne, C. Ged, 2010, The journal of gene medicine.

Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria.

I. Lamrissi‐Garcia, M. Lalanne, C. Ged, 2020, Blood.

Therapeutic potential of proteasome inhibitors in congenital erythropoietic porphyria

M. Lalanne, C. Ged, J. Blouin, 2013, Proceedings of the National Academy of Sciences.

Genetic background influences hepcidin response to iron imbalance in a mouse model of hemolytic anemia (Congenital erythropoietic porphyria).

I. Lamrissi‐Garcia, M. Lalanne, C. Ged, 2019, Biochemical and biophysical research communications.

An Orthotopic Model of Glioblastoma Is Resistant to Radiodynamic Therapy with 5-AminoLevulinic Acid

J. Boutin, M. Lalanne, J. Blouin, 2022, Cancers.

Neonatal bone marrow transplantation prevents liver disease in a murine model of erythropoietic protoporphyria.

P. Dubus, M. Lalanne, E. Richard, 2011, Journal of hepatology.

Generation of induced pluripotent stem cells-derived hepatocyte-like cells for ex vivo gene therapy of primary hyperoxaluria type 1.

P. Dubus, M. Lalanne, J. Blouin, 2019, Stem cell research.

Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cells.

I. Lamrissi‐Garcia, M. Lalanne, C. Ged, 2008, American journal of human genetics.

Missense UROS mutations causing congenital erythropoietic porphyria reduce UROS homeostasis that can be rescued by proteasome inhibition

M. Lalanne, C. Ged, J. Blouin, 2017, Human molecular genetics.

Metabolic correction of congenital erythropoietic porphyria with iPSCs free of reprogramming factors.

P. Dubus, M. Lalanne, C. Ged, 2012, American journal of human genetics.

Mutation-Specific Guide RNA for Compound Heterozygous Porphyria On-target Scarless Correction by CRISPR/Cas9 in Stem Cells

G. Cullot, J. Boutin, J. Toutain, 2020, Stem cell reports.

A knock-in mouse model of congenital erythropoietic porphyria.

P. Dubus, I. Lamrissi‐Garcia, M. Lalanne, 2006, Genomics.

Congenital erythropoietic porphyria: report of a novel mutation with absence of clinical manifestations in a homozygous mutant sibling.

E. Chouery, A. Mégarbané, M. Lalanne, 2004, The Journal of investigative dermatology.

Targeted gene therapy in human-induced pluripotent stem cells from a patient with primary hyperoxaluria type 1 using CRISPR/Cas9 technology.

P. Dubus, M. Lalanne, J. Blouin, 2019, Biochemical and biophysical research communications.

CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations

G. Cullot, J. Boutin, J. Toutain, 2019, Nature Communications.